CARMENA, a trial comparing the efficacy of sunitinib alone to that of nephrectomy followed by sunitinib in patients with primary metastatic renal cell carcinoma who require targeted therapy has demonstrated the non-inferiority of systemic therapy alone. The data provided by this and other studies argue for a lesser role of surgery in the management of these patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ljungberg, B. et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67, 913–924 (2015).
Mejean, A. et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1803675 (2018).
Mejean, A. et al. CARMENA: cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinoma—results of a phase III noninferiority trial [abstract]. J. Clin. Oncol. 36 (suppl.), LBA3 (2018).
Heng, D. Y. et al. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur. Urol. 66, 704–710 (2014).
Powles, T. et al. The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 60, 448–454 (2011).
Powles, T. et al. Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncol. 2, 1303–1309 (2016).
Bex, A. et al. Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Ann. Oncol. 28 (suppl. 5), md440.030 (2017).
Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx Renal. Cell 173, 581–594 (2018).
Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2018).
McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nature Med. 24, 749–757 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
A.B. has served on the advisory boards of Bristol-Myers Squibb (BMS), Genentech, Ipsen, Novartis, Pfizer, and Roche. All remunerations were made to an institutional account. He was the principle investigator of the European Organisation for Research and Treatment of Cancer (EORTC) SURTIME trial that was in part funded by an educational grant from Pfizer to the EORTC. J.H. has served on the advisory boards of BMS, Genentech, Merck, Novartis, Pfizer, and Roche. All remunerations were made to an institutional account.
Rights and permissions
About this article
Cite this article
Bex, A., Haanen, J. Cytoreductive nephrectomy in metastatic renal cancer — less is more. Nat Rev Clin Oncol 15, 595–596 (2018). https://doi.org/10.1038/s41571-018-0065-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-018-0065-4
